Market cap
$9 Mln
Recently Viewed
Clear All$0.01
$0.00
(-10.40%)
As on 09-Nov-2022 09:30EDT
Market cap
$9 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.9
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-43 Mln
ROE
-5.4 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.1
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
122,083,000
CFO
$-206.94 Mln
EBITDA
$-204.54 Mln
Net Profit
$-209.08 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Allena Pharmaceuticals (ALNA)
| -98.1 | -32.1 | -91.8 | -98.9 | -82.2 | -75.0 | -- |
|
BSE Sensex*
| -9.2 | 6.9 | -6.5 | -4.2 | 8.0 | 9.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|
|
Allena Pharmaceuticals (ALNA)
| -53.7 | -53.1 | -49.9 | -45.6 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Allena Pharmaceuticals (ALNA)
|
0.0 | 9.2 | 0.0 | -27.5 | -- | -243.1 | -- | 1.9 |
| 1.0 | 187.1 | 0.4 | -89.7 | -22,539.9 | -102.9 | -- | 2.6 |
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is... ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. Read more
Co-Founder & Chairman
Dr. Alexey L. Margolin Ph.D.
Co-Founder & Chairman
Dr. Alexey L. Margolin Ph.D.
Headquarters
Newton, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Allena Pharmaceuticals Inc (ALNA) is $0.01 (NASDAQ) as of 09-Nov-2022 09:30 EDT. Allena Pharmaceuticals Inc (ALNA) has given a return of -82.24% in the last 3 years.
Since, TTM earnings of Allena Pharmaceuticals Inc (ALNA) is negative, P/E ratio is not available.
The P/B ratio of Allena Pharmaceuticals Inc (ALNA) is 1.86 times as on 09-Nov-2022, a 56 discount to its peers’ median range of 4.23 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of Allena Pharmaceuticals Inc (ALNA) are Rs -- and Rs -- as of 02-May-2026.
Allena Pharmaceuticals Inc (ALNA) has a market capitalisation of $ 9 Mln as on 09-Nov-2022. As per SEBI classification, it is a Small Cap company.
Before investing in Allena Pharmaceuticals Inc (ALNA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.